BlueWhale Bio, Inc. – Dedicated to accelerating the growth and adoption of cell-based therapies.

▤ Summary

BlueWhale Bio highlights Synecta Activation as a technology designed to accelerate cell-based therapies. The offering aims to help teams reach target dose levels more reliably while lowering costs. It uses cell-derived nanoparticles to mimic immune cell activation and improve cell quality. The company also says the FDA has designated Synecta as an Advanced Manufacturing Technology. The message focuses on faster, more robust, and more cost-effective cell therapy manufacturing.

▦ Linked Companies